Javascript must be enabled to continue!
Digital Health Applications for Pharmacogenetic Clinical Trials
View through CrossRef
Digital health (DH) is the use of digital technologies and data analytics to understand health-related behaviors and enhance personalized clinical care. DH is increasingly being used in clinical trials, and an important field that could potentially benefit from incorporating DH into trial design is pharmacogenetics. Prospective pharmacogenetic trials typically compare a standard care arm to a pharmacogenetic-guided therapeutic arm. These trials often require large sample sizes, are challenging to recruit into, lack patient diversity, and can have complicated workflows to deliver therapeutic interventions to both investigators and patients. Importantly, the use of DH technologies could mitigate these challenges and improve pharmacogenetic trial design and operation. Some DH use cases include (1) automatic electronic health record-based patient screening and recruitment; (2) interactive websites for participant engagement; (3) home- and tele-health visits for patient convenience (e.g., samples for lab tests, physical exams, medication administration); (4) healthcare apps to collect patient-reported outcomes, adverse events and concomitant medications, and to deliver therapeutic information to patients; and (5) wearable devices to collect vital signs, electrocardiograms, sleep quality, and other discrete clinical variables. Given that pharmacogenetic trials are inherently challenging to conduct, future pharmacogenetic utility studies should consider implementing DH technologies and trial methodologies into their design and operation.
Title: Digital Health Applications for Pharmacogenetic Clinical Trials
Description:
Digital health (DH) is the use of digital technologies and data analytics to understand health-related behaviors and enhance personalized clinical care.
DH is increasingly being used in clinical trials, and an important field that could potentially benefit from incorporating DH into trial design is pharmacogenetics.
Prospective pharmacogenetic trials typically compare a standard care arm to a pharmacogenetic-guided therapeutic arm.
These trials often require large sample sizes, are challenging to recruit into, lack patient diversity, and can have complicated workflows to deliver therapeutic interventions to both investigators and patients.
Importantly, the use of DH technologies could mitigate these challenges and improve pharmacogenetic trial design and operation.
Some DH use cases include (1) automatic electronic health record-based patient screening and recruitment; (2) interactive websites for participant engagement; (3) home- and tele-health visits for patient convenience (e.
g.
, samples for lab tests, physical exams, medication administration); (4) healthcare apps to collect patient-reported outcomes, adverse events and concomitant medications, and to deliver therapeutic information to patients; and (5) wearable devices to collect vital signs, electrocardiograms, sleep quality, and other discrete clinical variables.
Given that pharmacogenetic trials are inherently challenging to conduct, future pharmacogenetic utility studies should consider implementing DH technologies and trial methodologies into their design and operation.
Related Results
Access Denied
Access Denied
Introduction
As social-distancing mandates in response to COVID-19 restricted in-person data collection methods such as participant observation and interviews, researchers turned t...
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
ABSTRACT
Background
Research infra-structure is essential for conducting phase III cancer clinical trials as its lack precludes...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Global trends and gaps in pharmacogenetic clinical trials: A cross-sectional analysis of ClinicalTrials.gov registrations
Global trends and gaps in pharmacogenetic clinical trials: A cross-sectional analysis of ClinicalTrials.gov registrations
Pharmacogenetics has emerged role in precision medicine, yet clinical translation remains limited. Understanding the scope and focus of clinical trials is crucial to inform future ...
Pharmacogenetics Clinical Decision Support Systems for Primary Care in England: Co-Design Study (Preprint)
Pharmacogenetics Clinical Decision Support Systems for Primary Care in England: Co-Design Study (Preprint)
BACKGROUND
Pharmacogenetics can impact patient care and outcomes through personalizing the selection of medicines, resulting in improved efficacy and a redu...
Exploring the Pharmacogenetic Landscape: Identification of Clinically Relevant Genotypes by a Nation-Wide Medical Testing Laboratory in Romania
Exploring the Pharmacogenetic Landscape: Identification of Clinically Relevant Genotypes by a Nation-Wide Medical Testing Laboratory in Romania
Background: Pharmacogenetic testing aims to assess the existence of a genetic predisposition that could influence the efficacy or safety of pharmacotherapy. The objective of the pr...
The influence of micro influencers and digital marketing on product purchasing decisions at tiktok shop in bengkulu city
The influence of micro influencers and digital marketing on product purchasing decisions at tiktok shop in bengkulu city
THE INFLUENCE OF MICRO-INFLUENCERS AND DIGITAL MARKETING ON PURCHASE DECISIONS OF TIKTOK SHOP CUSTOMERS IN BENGKULU CITY
Andhes Tiani Putri, Meylaty F
12Faculty Of Economic
E...
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19) pandemic situations without establishing clinical effectiveness or tailoring safety. A repurposing s...

